SCHEMBL1688075

SCHEMBL1688075

NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LONP1 P36776 13/20 0.68
PSMB5 P28074 11/20 0.68
PSMB8 P28062 10/20 0.68
PSMB9 P28065 10/20 0.68
PSMB6 P28072 10/20 0.68
PSMB10 P40306 10/20 0.68
PSMB11 A5LHX3 9/20 0.68
PSMA7 O14818 9/20 0.68
PSMB1 P20618 9/20 0.68
PSMA1 P25786 9/20 0.68
PSMA2 P25787 9/20 0.68
PSMA3 P25788 9/20 0.68
PSMA4 P25789 9/20 0.68
PSMA5 P28066 9/20 0.68
PSMB4 P28070 9/20 0.68
PSMB3 P49720 9/20 0.68
PSMB2 P49721 9/20 0.68
PSMA6 P60900 9/20 0.68
PSMA8 Q8TAA3 9/20 0.68
PSMB7 Q99436 9/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680573 1.00 LONP1 (0.68) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL13078869 0.90 CTSL (0.71) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL535688 0.90 LONP1 (0.71) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL535687 0.90 LONP1 (0.71) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL3926604 0.88 LONP1 (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL12521571 0.87 PSMB5 (0.74) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL3926607 0.86 LONP1 (0.67) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL25003548 0.85 CTSL (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL3083268 0.85 CTSL (0.69) LONP1PSMB5PSMB8PSMB9PSMB6
SCHEMBL25110920 0.85 LONP1 (0.72) LONP1PSMB5PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083760-A1 STABLE LIQUID BORTEZOMIB FORMULATIONS Riconpharma LLC (US) 2026-03-26 US disclosed
WO-2023078464-A1 EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海弼领生物技术有限公司 2023-05-11 WO disclosed
US-20220133757-A1 AQUEOUS COMPOSITIONS OF BORTEZOMIB SPES PHARMACEUTICALS INC. 2022-05-05 US disclosed
CN-110312727-A A kind of improved method for preparing borate 费森尤斯卡比肿瘤学有限公司 2019-10-08 CN disclosed
WO-2019151133-A1 MANUFACTURING METHOD FOR BORTEZOMIB CRYSTALS 日本化薬株式会社 2019-08-08 WO disclosed
WO-2018092724-A1 MOLECULAR KINETICS EVALUATION METHOD AND SCREENING METHOD 学校法人東京理科大学 2018-05-24 WO disclosed
WO-2018092723-A1 Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION 学校法人東京理科大学 2018-05-24 WO disclosed
WO-2012047845-A1 BORTEZOMIB FORMULATIONS STABILISED WITH BORIC APP PHARMACEUTICALS (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083760-A1 STABLE LIQUID BORTEZOMIB FORMULATIONS BCL6, BCL9, PSMD2 LONP1 2613/4885PSMB5 21/4885PSMB8 37/4885
US-20220133757-A1 AQUEOUS COMPOSITIONS OF BORTEZOMIB PSMG3, PSMA6, PSMA7 LONP1 1892/4885PSMB5 13/4885PSMB8 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.